MedTrace Logo

Characterization of Epithelial Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype

NCT05574673 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2026-02-27

No results posted yet for this study

Summary

This is a prospective observational multi-country, multi-center study of a large real-world cohort of first line (1L) epithelial ovarian cancer patients, exposed to standard of care (SOC) treatment stratified according to BRCA1/2 and HRD status.

Conditions

Interventions

OTHER

Standard of care

Patients receive standard of care treatment according to local and national guidelines

Sponsors & Collaborators

  • Nordic Society of Gynaecological Oncology - Clinical Trials Unit

    lead OTHER

Principal Investigators

  • Mansoor R Mirza, MD · NSGO-CTU

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-01
Primary Completion
2028-05-01
Completion
2032-07-01

Countries

  • Denmark

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05574673 on ClinicalTrials.gov